India & Gilead Sciences

India: India has generously donated emergency pharmaceutical supplies to the United States — Centers for Disease Control and Prevention to aid in the Ebola response in the Democratic Republic of the Congo, demonstrating its commitment to global health security.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

India: Merck plans to allow Indian manufacturers to produce generic alimatravir, potentially expanding access.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

India: India is partnering with the United States — Centers for Disease Control and Prevention to deliver medical supplies to aid in the Ebola response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

India: India, along with the African Union, postponed the India-Africa Forum Summit due to the evolving health situation in parts of Africa, demonstrating the international repercussions of the Ebola outbreak.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.